Toxoplasma gondii Infections Alter GABAergic Synapses and Signaling in the Central Nervous System

Justin M. Brooks,a Gabriela L. Carrillo,b Jianmin Su,b David S. Lindsay,b Michael A. Fox,b,dc Ira J. Bladera,e

Department of Microbiology and Immunology, SUNY at Buffalo School of Medicine, Buffalo, New York, USA; a Virginia Tech Carilion Research Institute, Roanoke, Virginia, USA; b Department of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA; c Department of Ophthalmology, SUNY at Buffalo School of Medicine, Buffalo, New York, USA

ABSTRACT During infections with the protozoan parasite Toxoplasma gondii, gamma-aminobutyric acid (GABA) is utilized as a carbon source for parasite metabolism and also to facilitate parasite dissemination by stimulating dendritic-cell motility. The best-recognized function for GABA, however, is its role in the nervous system as an inhibitory neurotransmitter that regulates the flow and timing of excitatory neurotransmission. When this pathway is altered, seizures develop. Human toxoplasmosis patients suffer from seizures, suggesting that Toxoplasma interferes with GABA signaling in the brain. Here, we show that while excitatory glutamatergic presynaptic proteins appeared normal, infection with type II ME49 Toxoplasma tissue cysts led to global changes in the distribution of glutamic acid decarboxylase 67 (GAD67), a key enzyme that catalyzes GABA synthesis in the brain. Alterations in GAD67 staining were not due to decreased expression but rather to a change from GAD67 clustering at presynaptic termini to a more diffuse localization throughout the neuropil. Consistent with a loss of GAD67 from the synaptic terminals, Toxoplasma-infected mice develop spontaneous seizures and are more susceptible to drugs that induce seizures by antagonizing GABA receptors. Interestingly, GABAergic protein mislocalization and the response to seizure-inducing drugs were observed in mice infected with type II ME49 but not type III CEP strain parasites, indicating a role for a polymorphic parasite factor(s) in regulating GABAergic synapses. Taken together, these data support a model in which seizures and other neurological complications seen in Toxoplasma-infected individuals are due, at least in part, to changes in GABAergic signaling.

IMPORTANCE Infections of the central nervous system can cause seizures. While inflammation in the brain has been proposed to initiate the onset of the seizures, relatively little is known about how inflammation impacts the structure and function of the neurons. Here we used a parasite called Toxoplasma gondii that infects the brain and showed that seizures arise due to a defect in signaling of GABA, which is the neurotransmitter primarily responsible for preventing the onset of seizures.

Neural activity within the brain is a balance of excitatory and inhibitory neurotransmission, and when excitatory activity becomes uncontrolled, seizures develop. A number of pathological conditions, including trauma, cancer, and inflammation, trigger seizures (1–3). Bacterial, viral, fungal, and parasitic infections of the brain also cause seizures, and several mechanisms by which seizures develop in response to infection have been proposed. These include breakdown of the blood-brain barrier, which allows an influx of either potassium, which increases neuronal firing, or autoantibodies, which target a number of proteins involved in neurotransmission (4). In addition, proinflammatory proteins, such as interleukin-1 beta (IL-1β) and cyclooxygenase 2, can cause immune system-mediated damage to neurons and glia that leads to the onset of seizures (4, 5). Although there is a general understanding of the initial infection-induced events that trigger seizures, significantly less is understood about how they actually impact the structure and function of neurons.

Toxoplasma gondii is a protozoan parasite that infects ~30% of the world’s population (6, 7). People and animals become infected following digestion of oocysts found in feline fecal material or tissue cysts in undercooked meat. Once in the gut, the parasite infects intestinal epithelial cells and converts to the rapidly growing tachyzoite form. Inflammatory cells are recruited to combat the infection and in turn become infected and hijacked by the parasite to disseminate from the gut to target tissues, including the brain, retina, and muscle (8–11). Within these tissues, gamma interferon (IFN-γ) is key for killing most of the tachyzoites, but some evade killing and transform into the quiescent bradyzoite form (7, 12). Bradyzoites then form tissue cysts by encasing themselves within a highly glycosylated and impermeable cyst wall that renders the bradyzoites resistant to killing by either the immune response or antiparasitic drugs (13). Tissue cysts can spontaneously rupture, and the released bradyzoites develop back into tachyzoites, which continue to replicate until an immune response is mounted (7). The parasite has a clonal population structure, and the strain types display differences in virulence and clin-
Type II and III strains, with LD$_{50}$s of 10 and 105, respectively, are infection, which is a time before a chronic infection is established. Toxoplasma modulates GABAergic signaling in monocytes and uses parasita plasma specifically alters GABAergic synapses. Toxoplasma (LD$_{100}$) of 1 parasite and death occurring within 10 days postinfection. First, a host’s ability to control parasite replication is key and those who are immunocompromised or were infected in utero are highly susceptible to developing disease (18, 19). Second, improperly regulated immune responses can cause immune system-mediated tissue damage (20). Finally, the disease type and severity are dictated by the genotypes of both the parasite and host (21–23). Symptomatic brain infection with Toxoplasma is known as toxoplasmic encephalitis (TE) and can clinically present with dizziness, headaches, and seizures. Despite the fact that TE has been clinically recognized for over 60 years (24), the effect that Toxoplasma and many other intracerebral pathogens have on neuronal structure and function is unknown. Therefore, the goal of this study was to use a murine TE model to identify the changes to neurons during TE that may underlie these neurological symptoms. Here, we report that mice with TE develop seizures due, in even between parasites belonging to the same strain type (17).

Three factors contribute to the onset and severity of toxoplasmosis. First, a host’s ability to control parasite replication is key and those who are immunocompromised or were infected in utero are highly susceptible to developing disease (18, 19). Second, improperly regulated immune responses can cause immune system-mediated tissue damage (20). Finally, the disease type and severity are dictated by the genotypes of both the parasite and host (21–23). Symptomatic brain infection with Toxoplasma is known as toxoplasmic encephalitis (TE) and can clinically present with dizziness, headaches, and seizures. Despite the fact that TE has been clinically recognized for over 60 years (24), the effect that Toxoplasma and many other intracerebral pathogens have on neuronal structure and function is unknown. Therefore, the goal of this study was to use a murine TE model to identify the changes to neurons during TE that may underlie these neurological symptoms. Here, we report that mice with TE develop seizures due, in part, to specific changes in the synaptic localization of glutamic acid decarboxylase 67 (GAD67). Since GAD67 is the key enzyme for the neuronal biosynthesis of gamma-aminobutyric acid (GABA), which is the major inhibitory neurotransmitter in the brain, these data indicate that Toxoplasma directly interferes with inhibitory neurotransmission and provides a molecular basis for the development of neurological complications in TE patients.

RESULTS

**Toxoplasma specifically alters GABAergic synapses.** Since Toxoplasma modulates GABAergic signaling in monocytes and uses GABA as a carbon source, and since GABA is the major inhibitory neurotransmitter in the brain (25, 26), we examined the effect of type II ME49 Toxoplasma infection on GABAergic neurons. Thus, mice were mock infected or infected with Toxoplasma tissue cysts of the type II ME49 strain and, 30 days later, their brains were harvested and stained to detect GAD67, which catalyzes the conversion of glutamate to GABA and is normally clustered at presynaptic GABAergic terminals in the mature brain (27, 28). Low-magnification images of whole-hemisphere brain sections revealed an apparent loss of GAD67 immunoreactivity in the caudal areas of hippocampi from type II ME49-infected mice as well as in the cortex and thalamus (Fig. 1A and B). The effect on GAD67 immunoreactivity appeared to be more widespread than the parasites were in the brain (according to the results of an assay using an anti-Toxoplasma antisera that detects both tachyzoite and bradyzoite antigens) (Fig. 1C and D). The effect of type II ME49 Toxoplasma on inhibitory GABAergic synapses appeared to be specific, as no apparent differences were seen in staining of the presynaptic glutamatergic markers vesicular glutamate transporter 1 (VGluT1) in the hippocampus, VGluT1 or VGluT2 in the cortex, and VGluT1 in the ventral horn of the spinal cord (Fig. 2; see also Fig. S1 in the supplemental material).

**Toxoplasma disrupts GAD67 presynaptic clustering.** Decreased GAD67 immunoreactivity could be due to either changes in GAD67 expression or its relocalization from distinct puncta at synaptic terminals to a more diffuse staining within the neuron. In fact, redistribution of presynaptic machinery is known to occur during development, when transsynaptic signals induce the clustering of diffusely localized presynaptic molecules into discrete clusters specifically at synaptic sites (29, 30). To discriminate between these two possibilities, we compared brains of mock-infected and type II ME49-infected mice for mRNA levels of gad1 (the gene that encodes GAD67) and gphn, which encodes gephyrin, a scaffolding protein localized to the postsynaptic specializations of GABAergic synapses. No significant differences were observed in gad1 or gphn transcript levels (Fig. 3A). Similarly, no statistically significant differences in the abundances of the pro-

---

**FIG 1** Decreased GABAergic synaptic protein staining in type II ME49 Toxoplasma-infected brains. (A and B) GAD67 immunoreactivity in mock-infected (A) or type II ME49 Toxoplasma-infected (B) brains. (C and D) Detection of type II ME49 Toxoplasma tachyzoites (white arrow in panel D) and bradyzoites (arrowhead in panel D). The image in panel D is a high-magnification image of the boxed in area in panel C. Scale bars, 1 mm (A, B, and C) and 0.25 mm (D). Lines appear in the images due to lack of overlap during image acquisition of each brain.

**FIG 2** Unaltered glutamatergic synaptic protein staining in type II ME49 Toxoplasma-infected brains. (A and B) VGluT1 immunoreactivity in mock-infected or type II ME49 Toxoplasma-infected hippocampi. Scale bars, 0.2 mm. (C and D) VGluT2 immunoreactivity in mock-infected or type II ME49 Toxoplasma-infected cortexes. Scale bars, 0.4 mm.

---

Brooks et al.
teins were noted in parasite-infected brains (P/H11022 0.7 [two-tailed, unpaired t test]) (Fig. 3B). Similarly to previous work (28), high-magnification analysis revealed that GAD67 localized to discrete synaptic puncta in the stratum pyramidale and other regions in the hippocampi of mock-infected mice (Fig. 3C). In contrast, GAD67 staining in these regions from the infected animals no longer appeared enriched at synaptic release sites. To quantify these differences, GAD67-stained images were binarized and the percent area of binarized immunoreactivity was calculated. Despite the minimal changes in overall GABA levels (Fig. 3A and B), these analyses revealed a statistically significant increase in the area containing binarized GAD67 immunoreactivity in the parasite-infected brains (Fig. 3D). Similarly to VGluT1 staining in Fig. 2, binary image analysis revealed no significant differences in the levels of VGluT1 coverage between mock-infected and parasite-infected brains. The impact of type II ME49 Toxoplasma on GAD67 localization was not restricted to the hippocampus. GAD67 localization was similarly affected in the lateral geniculate nucleus (LGN) of the thalamus and in the ventral horn of the spinal cord (see Fig. S1 and S2 in the supplemental material). Moreover, GAD67 remained restricted to neurons since it did not colocalize with either Iba1 (a macrophage marker)-expressing or glial fibrillary acidic protein (GFAP) (an astrocyte marker)-expressing cells (see Fig. S3). These data indicate that type II ME49 Toxoplasma globally redistributes GAD67 away from GABAergic nerve terminals.

Toxoplasma-infected mice develop spontaneous seizures. GAD67 clusters within presynaptic terminals due to its tethering to GABAergic synaptic vesicles, which is a process thought to support efficient and rapid neurotransmitter loading into the synaptic vesicles (28, 31). Thus, alterations in GAD67 localization significantly impact GABAergic neurotransmission. We therefore assessed the neural and muscular activity of mock-infected or type II ME49 parasite-infected mice with electroencephalography (EEG) and electromyography (EMG) over a period of 5 days. EEGs were recorded from skull electrodes implanted over motor and sensory cortices of the mice, and EMGs were recorded from the nuchal musculature. EEG and EMG analyses revealed significant increases in seizure activity in the infected mice, as defined as greater than 30 s of sustained high-amplitude, high-frequency neural and muscular activity (Fig. 4A and B). Within the 5 days of recording, infected mice experienced an average of 11.3 ± 5.3 (standard error of the mean [SEM]) of these seizure events (n = 8) (Fig. 4D). In contrast, mock-infected mice experienced an average of 0.5 ± 0.3 (SEM) of these events during the same recording period (n = 6), a difference that was statistically significant (P < 0.05 by Tukey-Kramer honestly significant difference [HSD] test) (Fig. 4D). EMG recordings further revealed examples in type II ME49 parasite-infected mice of generalized motor seizures that persisted for >15 min (Fig. 4C). These data indicate that, similarly to human toxoplasmosis patients, type II ME49 Toxoplasma-infected mice develop seizures.

It has been widely speculated that interictal spikes of neural activity (rapid [<250 ms] single spikes of neural activity in EEG traces) may be predictive of seizure activity (32). For this reason, we also quantified the number of “spiking” events (defined as high-amplitude brain activity with <1 spike/s) in mock-infected and type II ME49 parasite-infected mice (33). In contrast to the significant impact of infection on seizure activity, no significant differences were seen in the numbers of “spiking” events between infected and mock-infected brains: an average of 18.5 ± 9.4 (SEM) spiking events were observed in type II ME49-infected
brains during 5 days of recording versus 9.5 ± 4.6 spiking events in mock-infected controls ($P > 0.1$ [Tukey-Kramer HSD test]) (Fig. 4E and F).

**Toxoplasma-infected mice develop more-severe seizures in response to GABA antagonists.** To assess the impact of altered GAD67 localization on epileptogenic activity in type II ME49 Toxoplasma-infected mice, we compared the levels of duration and intensity of seizures in mock-infected and parasite-infected mice treated with pentylenetetrazol (PTZ)—a GABA receptor antagonist that induces seizures (34, 35). Thirty days after mice were either mock infected or infected with type II ME49 parasite, a single injection of PTZ was administered, EMG traces were recorded, and visual seizure scores were noted every minute for 15 min. Results demonstrated that *Toxoplasma* infection increased seizure scores and also decreased the time needed for the mouse data to reach plateau scores (Fig. 5). Thus, the onset and magnitude of PTZ-induced seizures were increased in parasite-infected mice.

**GAD67 relocalization between Toxoplasma strains is a polymorphic phenotype.** Four *Toxoplasma* haplotypes (I to III and X [or 12]) predominate in North America and Europe (15, 36–38). Of these, both type II and III strains are able to disseminate to the brain, establish chronic infections, and form tissue cysts (17, 36, 39). But genetic differences between these strains impact virulence, drug resistance, and specific host-pathogen interactions (40–45). Thus, we tested whether GAD67 localization was similarly affected by type II and III strains by infecting mice with either type II ME49 or CEP type III CEP strain parasites. We found that GAD67 staining in the hippocampi of type III CEP-infected mice closely resembled the punctate staining in uninfected animals (Fig. 6A to C). Binarized images of GAD67 immunoreactivity from mock-infected and type II ME49-infected or type III CEP-
infected brains were quantified. We found that GAD67 immuno-reactivity significantly increased ($P < 0.0001$ by analysis of variance [ANOVA] with Tukey’s post hoc test) in the type II ME49-infected but not type III CEP-infected brains (Fig. 6D).

To further test our hypothesis that GAD67 mislocalization is associated with the development of seizures in Toxoplasma-infected mice, we compared the responses of mock-infected, type II ME49-infected, and type III CEP-infected mice to PTZ. We found that, in contrast to the severe PTZ-induced seizures in the type II ME49-infected mice, the seizures in the type III CEP-infected mice were comparable to those in the mock-infected mice (Fig. 6E). These data therefore indicate that GAD67 mislocalization and seizure susceptibility represent a polymorphic phenotype following Toxoplasma infections and are not a general feature of the presence of Toxoplasma in the brain.

**DISCUSSION**

A key function for GABA in the nervous system is to regulate the timing, magnitude, and flow of excitatory neurotransmission, and defects in GABAergic signaling cause seizures (46). Decreasing synaptic release from inhibitory nerve terminals can reduce GABA signaling, and GAD localization to synaptic vesicles in presynaptic terminals leads to decreased GABA release since this ensures efficient GABA synthesis at synaptic termini (28, 31). Here, we show for the first time that a microbial infection of the CNS leads to mislocalization of GAD67. These data are significant because GAD67 is the GAD isoform responsible for the majority of GABA synthesis in the mammalian brain, whereas other GAD isoforms appear to have a more auxiliary role in GABA production and inhibitory neurotransmission (47–49). The anticipated outcome of such alterations would be increased spontaneous and drug-inhibitory neurotransmission (47–49). The anticipated outcome of increased susceptibility of type II ME49 Toxoplasma-infected mice to drug-induced seizures. (A) Five days after mice were analyzed for spontaneous seizures, they were injected with PTZ (40 mg/kg), and EEG/EMG data were recorded for 15 min. The data shown represent typical EMG traces from a mock-infected mouse (top) and a type II ME49 parasite-infected mouse (bottom). Notice the increased strength and intensity of muscular activity in the type II ME49 Toxoplasma-infected mouse. (B) Averages (± SEM) of seizure score data recorded every minute for 15 min after injection of PTZ. * $P < 0.05$ (unpaired, two-tailed t test).
Toxoplasma type II ME49 and type III CEP strains were routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum as previously described (58). Tissue cysts were passed between C57BL/6 mice by intra-peritoneal injection of 10 cysts. Experimental infections were performed by injecting 10 brain cysts into 0.2 ml of DMEM. All mice were purchased from Jackson Laboratories and used at between 6 and 12 weeks of age.

Immunohistochemistry. Mice were exsanguinated and then perfused with 4% paraformaldehyde–phosphate-buffered saline (PBS). Brains were harvested, cryosectioned (16 μm), and stained as described previously (59, 60). Tissue cysts were passed between C57BL/6 mice by intra-peritoneal injection of 10 cysts. Experimental infections were performed by injecting 10 brain cysts into 0.2 ml of DMEM. All mice were purchased from Jackson Laboratories and used at between 6 and 12 weeks of age.

The following antibodies were used: rabbit anti-vGluT1 (1:500 dilution) and antibody against rabbit IgG (1:500 dilution).

FIG 6 GAD67 mislocalization and drug-induced seizure are polymorphic responses in Toxoplasma-infected brains. (A to C) Representative images of coronal sections from mock-infected (A), type II ME49-infected (B), and type III CEP-infected (C) mice 30 days postinfection. Scale bars, 500 μm. Expanded images show high-magnification views of hippocampus CA3 regions. Scale bars, 50 μm. (D) Quantification of percent GAD67 staining following binarizing of images. *, P < 0.001 (one-way ANOVA with Tukey’s post hoc test; n ≥ 3 mice for each group). (E) Averages (± SEM) of seizure scores of mock-infected, type II ME49-infected, and type III CEP-infected mice (30 days postinfection) recorded every minute for 15 min after injection of PTZ. Each group represents score data for a minimum of 6 mice. *, statistically significant difference between type II ME49-infected and mock-infected mice only (P < 0.05 [one-way ANOVA with Tukey’s post hoc test]). #, statistically significant difference between type II ME49 and both mock-infected and type III CEP-infected mice (P < 0.05 [one-way ANOVA with Tukey’s post hoc test]).
tion) and rabbit anti-α-GluT2 (1:500 dilution) were from Synaptic Systems, Göttingen, Germany, rabbit anti-GFAP (1:1,000 dilution) was from Dako, Carpinteria, CA, rabbit anti-Iba1 (1:1,000 dilution) was from WAKO Chemicals USA, Inc., Richmond, VA, and mouse anti-GAD67 (1:500 dilution) was from Millipore, Temecula, CA. Neurotrac 640 deep red fluorescent Nissl stain was also used according to the protocol of the manufacturer (Life Technologies, Eugene, OR). Anti-Toxoplasma sera (1: 250 dilution) that recognize both tachyzoites and bradyzoites were kindly provided by Tajie Harris. All conjugated secondary antibodies were purchased from Invitrogen (Carlsbad, CA) or Jackson ImmunoResearch (West Grove, PA).

**Binary quantification.** The area within an image containing immunoreactivity was determined as previously described (61). Briefly, single channels of each image were converted to binary images using ImageJ software (see Fig. S1 in the supplemental material as an example). The percent area containing positive immunoreactivity in each image was then determined in ImageJ. A Student’s t test was used to test for statistical significance, and at least 9 images were collected from a minimum of three mock-infected and type II ME49-infected animals.

**Western blotting.** Brains were harvested from decapitated mock-infected or parasite-infected mice, and coronal cortical sections (500 μm thick) were cut in ice-cold diethylpyrocarbonate (DEPC)-PBS and then flash frozen in liquid nitrogen. The tissue was then homogenized in radioimmunoprecipitation assay (RIPA) buffer supplemented with Protease Inhibitor Cocktail (Roche, Basel, Switzerland) as previously described (58). Lysates (30 μg/sample) were separated by SDS-PAGE and subjected to Western blotting with antibodies against GAD67 and β-actin (Cell Signaling, Inc., Danvers, MA) and anti-gephyrin antibodies (Synaptic Systems) diluted in Odyssey blocking buffer (Li-COR, Lincoln, NE) containing 0.1% Tween 20. Secondary antibodies were purchased from LI-COR. Images were captured using a Li-COR Odyssey Imaging system and processed using the manufacturer’s software.

**RT-PCR.** RNA was prepared from coronal cortical sections using a Stratagene Absolutely RNA purification kit (La Jolla, CA) and converted to cDNA with Superscript III reverse transcriptase (RT; Invitrogen). Target gene expression levels were determined by RT-PCR using the threshold cycle ($2^{- \Delta \Delta CT}$) method as previously described (62). The following primer sets were used: for the β-actin gene, 5′-GAGGGCAGAGGTCACTCAATTG-3′ and 5′-CACAGGATTCCTACATCCAAAG-3′; for the gephyrin gene, 5′-ACCTCCAGGCAGAAATACAC-3′ and 5′-GCTACAGAGGACGCEPTCA-3′; and for the GAD1 gene, 5′-CTCCACGCGACACAGATATGA-3′ and 5′-TGCTGTTGGAGATGACATCACCAGA-3′.

**Spontaneous seizure recordings.** Unless otherwise noted, all EEG/EMG hardware and software (including a 3-channel, tethered EEG/EMG system) were from Pinnacle Technologies (Lawrence, KS). Mock-infected and type II ME49-infected mice were used. Seizures were identified as consisting of high-amplitude, high-frequency neural and muscular activity that persisted for more than 30 s. A total of 8 mice per group were utilized for analysis.

**PTZ-induced seizures.** Mice were injected with PTZ (40 mg/kg of body weight)—0.2 ml PBS and then visually monitored for 15 min while blind to their infection status. Seizures were scored manually every minute thereafter with the following scoring criteria: 0, normal activity; 1, reduced motility and prostate position; 2, partial clonus; 3, generalized clonus; 4, tonic-clonic seizure; 5, death. The PTZ dose was chosen since it reproducibly triggers high rates of mild seizures in C57/B6 mice (90% of wild-type mice develop mild seizures) but with a low (~10%) fatality rate (63).

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/MBio.01428-15/-/DCSupplemental.

**ACKNOWLEDGMENTS**

We thank Tajie Harris for providing the anti-Toxoplasma sera and Emma Wilson for helpful discussions and sharing of unpublished data.

**REFERENCES**

1. Xu D, Miller SD, Koh S. 2013. Immune mechanisms in epileptogenesis. Front Cell Neurosci 7:195. http://dx.doi.org/10.3389/fncel.2013.00195.
2. Annegers JF, Hauser WA, Coan SP, Rocca WA. 1998. A population-based study of seizures after traumatic brain injuries. N Engl J Med 338: 20–24. http://dx.doi.org/10.1056/NEJM199810103381504.
3. Avila EK, Graber J. 2010. Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep 10:690–667. http://dx.doi.org/10.1007/s11910-009-0080-2.
4. Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, Hallene K, Digiglio T, Franic L, Najm I, Janigro D. 2007. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 48:732–742. http://dx.doi.org/10.1111/j.1528-1167.2007.00988.x.
5. Pappas G, Rosnous N, Falagas ME. 2009. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 39:1385–1394. http://dx.doi.org/10.1016/j.ijpara.2009.04.003.
6. Weiss LM, Kim K. 2000. The development and biology of bradyzoites of Toxoplasma gondii. Front Biosci 5:S391–D405. http://dx.doi.org/10.2741/Weiss.
7. Bierly AL, Shufesky WJ, Sukhumavasi W, Morelli AE, Denkers EY. 2008. Dendritic cells expressing plasmacytoid marker PDCA-1 are Trojan horses during Toxoplasma gondii infection. J Immunol 181:8485–8491. http://dx.doi.org/10.4049/jimmunol.181.12.8485.
8. Lambert H, Hitziger N, Dellacasa I, Svensson M, Barragan A. 2006. Induction of dendritic cell migration upon Toxoplasma gondii infection reveals a potential mechanism for parasite dissemination. Cell Microbiol 8:1611–1623. http://dx.doi.org/10.1111/j.1462-3822.2006.00735.x.
9. Courret N, Durche S, Sonigo P, Milon G, Buzoni-Gatel D, Tardieux I. 2006. CD11c+ and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 107:309–316. http://dx.doi.org/10.1182/blood-2005-02-0666.
10. Coombes JL, Charsar BA, Han S-, Halkias J, Chan SW, Koshy AA, Striepen B, Robey EA. 2006. Motility of Toxoplasma gondii tachyzoites to the brain. Proc Natl Acad Sci U S A 103:E1913–E1922. http://dx.doi.org/10.1073/pnas.120272110.
11. Sturge CR, Varoyevsky F. 2014. Complex immune cell interplay in the gamma interferon response during Toxoplasma gondii infection. Infect Immun 82:3090–3097. http://dx.doi.org/10.1128/IAI.01722-14.
12. Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, Kim K, Weiss LM. 2013. The Toxoplasma gondii cyst wall protein CST1 is critical

November/December 2015 Volume 6 Issue 6 e01428-15

mbio.asm.org 7

Toxoplasma Alters Host GABAergic Signaling
for cyst wall integrity and promotes bradyzoite persistence. PLoS Pathog 9:e1003823. http://dx.doi.org/10.1371/journal.ppat.1003823.

14. Sibley LD, Ajioka JW. 2008. Population structure of Toxoplasma gondii: clonal expansion driven by infrequent recombination and selective sweeps. Annu Rev Microbiol 62:329–351. http://dx.doi.org/10.1146/annurev.micro.62.081707.162925.

15. Dubey JP, Velmurugan GV, Rajendran C, Yabsley MJ, Thomas NJ, Beckmen KB, Sinnett D, Ruid D, Hart J, Fair PA, McFee WE, Shearn-Bochsler V, Kwoch OCH, Ferreira LR, Choudhary S, Faria EB, Zhou H, Felix TA, Su C. 2011. Genetic characterisation of Toxoplasma gondii in wildlife from North America revealed widespread and high prevalence of the fourth clonal type. Int J Parasitol 41:1139–1147. http://dx.doi.org/10.1016/j.ijpara.2011.06.005.

16. Howe DK, Summers BC, Sibley LD. 1996. Acute virulence in mice is associated with markers on chromosome VIII in Toxoplasma gondii. Infect Immun 64:5193–5198.

17. Fux B, Nawas J, Khan A, Gill DB, Su C, Sibley LD. 2007. Toxoplasma gondii strains defective in oral transmission are also defective in developmental stage differentiation. Infect Immun 75:2580–2590. http://dx.doi.org/10.1128/IAI.00855-07.

18. Liu Y, Zhao M, Xu X, Liu X, Zhang H, Jiang Y, Zhang L, Hu X. 2014. Adoptive transfer of Treg cells counteracts adverse effects of Toxoplasma gondii infection on pregnancy. J Infect Dis 210:1435–1443. http://dx.doi.org/10.1093/infdis/jiu265.

19. Luft BJ, Brooks RG, Conley FK, McCabe RE, Remington JS. 1984. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 252:913–917.

20. Gazzinelli RT, Wysocka M, Heny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A. 1996. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 157:798–805.

21. Grigg ME, Bonnefoy S, Hehl AB, Suzuki Y, Boothroyd JC. 2001. Success and virulence in Toxoplasma as the result of sexual recombination between two distinct ancestors. Science 294:161–165. http://dx.doi.org/10.1126/science.1061888.

22. Witola WH, Mui E, Hargrave A, Liu S, Hypolite M, Montpetit A, Cavaillès P, Bisanz C, Cesbron-Delauw M, Fournier GJ, McLeod R. 2011. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytes. Infect Immun 79:756–766. http://dx.doi.org/10.1128/IAI.00898-10.

23. Tan TG, Mui E, Cong H, Witola WH, Montpetit A, Muench SP, Sidney J, Alexander J, Sette A, Grigg ME, Ma ewal A, McLeod R. 2010. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine 28:3977–3989. http://dx.doi.org/10.1016/j.vaccine.2010.03.028.

24. Sabin AB, Feldman HA. 1949. Chorioretinopathy associated with other evidence of cerebral damage in childhood; a syndrome of unknown etiology. Annu Rev Cell Dev Biol 23:57–59.

25. MacRae J, Sheiner L, Nahid A, Tonkin C, Striepen B, McConville M. 2007. Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature 445:324–327. http://dx.doi.org/10.1038/nature05395.

26. Behnke MS, Khan A, Sibley LD. 2015. Genetic mapping reveals that sinefuzing resistance in Toxoplasma gondii is controlled by a putative amino acid transporter locus that can be used as a negative selectable marker. Eukaryot Cell 14:140–148. http://dx.doi.org/10.1126/EC.002292-14.

27. Behnke MS, Khan A, Wootton JC, Dubey JP, Tang K, Sibley LD. 2011. Virulence differences in Toxoplasma mediated by amplification of a family of polymorphic pseudokinases. Proc Natl Acad Sci U S A 108:9631–9636. http://dx.doi.org/10.1073/pnas.1015338108.

28. Taylor S, Barragan A, Su C, Fux B, Fentress SJ, Tang K, Beatty WL, Hajj HE, Jerome M, Behnke MS, White M, Wootton JC, Sibley LD. 2006. A secreted serine–threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 314:1776–1783. http://dx.doi.org/10.1126/science.1133690.

29. Kanaani J, Diacovo MJ, El-Husseini Ael D, Bredt DS, Baekkeskov S. 2004. Palmitoylation controls trafficking of GAD65 from Golgi membranes to axon-specific endosomes and a Rab5a-dependent pathway to presynaptic clusters. J Cell Sci 117:2003–2013. http://dx.doi.org/10.1242/jcs.01010.

30. Staley RJ, Dudek FE. 2006. Intertrial spikes and epileptogenesis. Epilepsy Res 70:149–202. http://dx.doi.org/10.1016/j.eplepsyres.2006.01.035.

31. Bergstrom RA, Choi JH, Manduca A, Shin H, Worrell GA, Howe CL. 2013. Automated identification of multiple seizure-related and interictal epileptiform event types in the EEG of mice. Sci Rep 3:1483. http://dx.doi.org/10.1038/srep01483.

32. Ramanjaneyulu R, Ticku MK. 1984. Interactions of pentamethyl-enetetrazole and tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA receptor-ionophore complex. Prog Neuro-Psychopharmac 9:337–345. http://dx.doi.org/10.1016/0140-440X(84)90028-4.

33. Huang RQ, Bell-Horner CL, Dibas MI, Covey DF, Drewe JA, Dillon GH. 2001. Pentylentetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action. J Pharmacol Exp Ther 298:986–995.

34. Howe DK, Sibley LD. 1995. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis 172:1561–1566. http://dx.doi.org/10.1093/infdis/172.6.1561.

35. Khan A, Dubey JP, Su C, Ajioka JW, Rosenthal BM, Sibley LD. 2011. Genetic analyses of atypical Toxoplasma gondii strains reveal a fourth clonal lineage in North America. Int J Parasitol 41:645–655. http://dx.doi.org/10.1016/j.ijpara.2011.01.005.

36. Miller M, Miller W, Conrad P, James E, Melli A, Leutenegger C, Daubritz H, Packham A, Paradies D, Harris M, Ames J, Jessup DA, Wei-Keefer K, Grigg ME. 2007. Type X Toxoplasma gondii in a wild muskellunge and terrestrial carnivores from coastal California: new linkages between terrestrial mammals, runoff and toxoplasmosis of sea otters. Int J Parasitol 38:1319–1328. http://dx.doi.org/10.1016/j.ijpara.2008.02.005.

37. Sibley LD, Boothroyd JC. 1992. Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature 359:82–85. http://dx.doi.org/10.1038/359082a0.

38. Saiji JP, Boyle JP, Coller S, Taylor S, Sibley LD, Brooke-Powell ET, Ajioka JW, Boothroyd JC. 2006. Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Science 314:1780–1783. http://dx.doi.org/10.1126/science.1133690.

39. Saiji JP, Coller S, Boyle JP, Jerome ME, White MW, Boothroyd JC. 2007. Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature 445:324–327. http://dx.doi.org/10.1038/nature05395.
49. Asada H, Kawamura Y, Maruyama K, Kume H, Ding R, Kanbara N, Kuzume H, Sanbo M, Yagi T, Obata K. 1997. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A 94:6496–6499. http://dx.doi.org/10.1073/pnas.94.12.6496.

50. Krook-Magnuson E, Armstrong C, Oijala M, Soltesz I. 2013. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat Commun 4:1376.

51. Luft BJ, Remington JS. 1992. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 15:211–222. http://dx.doi.org/10.1093/clinids/15.2.211.

52. Ngoungou EB, Bhalla D, Nzoghe A, Darde ML, Preux PM. 2015. Toxoplasmosis and epilepsy—systematic review and meta analysis. PLoS Negl Trop Dis 9:e0003525.

53. Koshy AA, Dietrich HK, Christian DA, Melehani JH, Shastri AJ, Hunter CA, Boothroyd JC. 2012. Toxoplasma co-opts host cells it does not invade. PLoS Pathog 8:e1002825. http://dx.doi.org/10.1371/journal.ppat.1002825.

54. Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, Yolken R, Szoke A, Leboyer M, de Haan L. 2015. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand 132:161–179 http://dx.doi.org/10.1111/acps.12423.

55. Singh R, Su J, Brooks J, Terauchi A, Umemori H, Fox MA. 2012. Fibroblast growth factor 22 contributes to the development of retinal nerve terminals in the dorsal lateral geniculate nucleus. Front Mol Neurosci 4:61. http://dx.doi.org/10.3389/fnmol.2011.00061.

56. Phelps ED, Sweeney KR, Blader IJ. 2008. Toxoplasma gondii rhoptry discharge correlates with activation of the EGR2 host cell transcription factor. Infect Immun 76:4703–4712. http://dx.doi.org/10.1128/IAI.01447-07.

57. Takahashi H, Katayama K, Sohya K, Miyamoto H, Prasad T, Matsutomo Y, Ota M, Yasuda H, Tsumoto T, Araujo J, Craig AM. 2012. Selective control of inhibitory synapse development by Slitrk3-PTPdelta trans-synaptic interaction. Nat Neurosci 15:389–398. http://dx.doi.org/10.1038/nn.3040.